Table 3 Patterns of DPP-4i use, N = 105
From: Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital
Parameters/characteristics | n (%) |
|---|---|
Types of DPP-4i | |
Vildagliptin | 39 (37.1) |
Sitagliptin | 32 (30.5) |
Saxagliptin | 26 (24.8) |
Linagliptin | 8 (7.6) |
Duration of use (months) a | 29.7 ± 19.8 |
< 24 | 46 (43.8) |
≥ 24 | 59 (56.2) |
Fixed-dose combination (FDC) tablets | |
Vildagliptin/Metformin | 27 (25.7) |
Sitagliptin/Metformin | 21 (20.0) |
Saxagliptin/Metformin | 18 (17.1) |
Metformin | |
FDC | 66 (62.9) |
Add on | 29 (27.6) |
Total | 95 (90.5) |
Other concurrent antidiabetics | |
Insulin | 59 (56.2) |
Gliclazide IR/MR | 27 (25.7) |
Glibenclamide | 1 (1.0) |
Acarbose | 3 (2.9) |
None | 28 (26.7) |
Types of insulin therapy | |
Basal bolus | 28 (26.7) |
Premixed | 15 (14.3) |
Bolus only | 15 (14.3) |
Basal only | 1 (1.0) |
Adherence | |
Good | 58 (55.2) |
Poor | 13 (12.4) |
Not documented | 34 (32.4) |